NiKang Therapeutics is a biotech company focused on discovering and developing small molecule oncology medicines.
NiKang Therapeutics is an early-stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs. Its discovery approach is informed by target structure biology and capitalizes on structure-based drug design enabling a rapid and efficient discovery and development of proprietary drug candidates with the most desirable pharmacological features into clinical studies.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
May 26, 2021 | Series C | $200M | 2 | — | — | Detail |
Sep 14, 2020 | Series B | $50M | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Lilly Asia Ventures | — | Series C |
Pavilion Capital | — | Series C |
Octagon Investments | — | Series B |